Supplementary_tables: Prognostic implications of PD-L1 expression in patients with angiosarcoma

Background: There are limited data on the feasibility of
programmed death ligand-1 (PD-L1) expression as a prognostic biomarker in
metastatic angiosarcoma. Materials & Methods: We retrospectively collected
and analyzed the data on PD-L1 expression in 70 angiosarcoma patients who were
diagnosed at our center between 2005 and 2019. Results: Thirteen (19%) patients
had PD-L1 expression. Metastatic angiosarcoma patients who were PD-L1-negative
(n=24) showed longer median progression-free survival (4.9 vs. 1.6 months;
p=0.04) and median overall survival (OS; 10.9 vs. 5.4 months; p=0.01) than
those who were PD-L1-positive (n=4). PD-L1 status proved to be a significant
factor for OS. Conclusions: Metastatic angiosarcoma patients with PD-L1
expression showed shorter survival. PD-L1 status is an independent prognostic
factor for OS in metastatic angiosarcoma patients.

背景：目前关于程序性死亡配体1（programmed death ligand-1，PD-L1）表达作为转移性血管肉瘤预后生物标志物的可行性相关研究数据十分有限。
材料与方法：本研究回顾性收集并分析了2005年至2019年间于本中心确诊的70例血管肉瘤患者的PD-L1表达相关数据。
结果：共计13例（19%）患者存在PD-L1表达。PD-L1阴性的转移性血管肉瘤患者（n=24）的中位无进展生存期（4.9个月 vs 1.6个月；p=0.04）与中位总生存期（overall survival，OS；10.9个月 vs 5.4个月；p=0.01）均显著长于PD-L1阳性患者（n=4）。PD-L1状态被证实是影响OS的重要相关因素。
结论：存在PD-L1表达的转移性血管肉瘤患者生存期更短。PD-L1状态是转移性血管肉瘤患者OS的独立预后因素。